Position of the Transparency Council – Kalydeco (ivacaftor)
At its meeting on 28 October 2024, the Transparency Council adopted position No. 115/2024 on the evaluation of the drug Kalydeco (ivacaftor) in the framework of the drug program B.112 “Treatment of patients with cystic fibrosis (ICD-10: E84)”